{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=25", "query": { "condition": "Adenocarcinoma of Colon", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 706, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Colon&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:13:26.936Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Breast Cancer", "Gastric Cancer", "Non Small Cell Lung Cancer", "Cervical Cancer", "Endocervical Cancer", "Squamous Cell Carcinoma of Head and Neck", "Bladder Urothelial Cancer", "Colorectal Cancer", "Esophageal Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Prostate Cancer", "Melanoma", "Mesothelioma", "Cholangiocarcinoma" ], "interventions": [ { "name": "NGM438", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2022-05-11", "completion_date": "2025-06", "has_results": false, "last_update_posted_date": "2024-04-01", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 6, "location_summary": "Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05311618" }, { "nct_id": "NCT06885424", "title": "A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor Cancer", "Solid Tumor, Unspecified, Adult", "Colorectal Carcinoma", "Colorectal Carcinoma (CRC)", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Pancreatic Cancer", "NSCLC", "Mesothelioma", "Ovarian Cancer", "Ovarian Carcinoma", "Head and Neck (HNSCC)", "Head and Neck Cancer", "Renal Cell Carcinoma (Kidney Cancer)", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "No additional intervention administered in this long term follow-up study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-07-31", "completion_date": "2040-03-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 3, "location_summary": "Gilbert, Arizona • Rochester, Minnesota • New York, New York", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06885424" }, { "nct_id": "NCT05029882", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Solid Tumors", "Gastroesophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Trifluridine/Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2021-10-13", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 18, "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05029882" }, { "nct_id": "NCT00019513", "title": "Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer", "Lung Cancer", "Lymphoma", "Pancreatic Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "1998-08", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019513" }, { "nct_id": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "LY4066434.", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2024-10-21", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06607185" }, { "nct_id": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Carcinoma (NSCLC)", "Melanoma", "Bladder Cancer", "Colorectal Cancer", "Gastric Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CM-24 (MK-6018)", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (MK-3475)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2015-02", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2020-08-27", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 2, "location_summary": "Los Angeles, California • New Haven, Connecticut", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346955" }, { "nct_id": "NCT03366155", "title": "Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Liver Metastases", "Colorectal Adenocarcinoma", "Colorectal Cancer With Hepatic Metastases", "Colorectal Carcinoma" ], "interventions": [ { "name": "Codman 3000 constant flow pump catheter", "type": "DEVICE" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "FUDR-Dex", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5FU", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "HAIP installation", "type": "PROCEDURE" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "Medtronic SynchroMed II Pump", "type": "DEVICE" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT C/A/P", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Angiogram (abdomen)", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor and normal liver biopsy", "type": "PROCEDURE" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-06-24", "completion_date": "2025-11-13", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03366155" }, { "nct_id": "NCT00553683", "title": "Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Gastric Cancer", "Liver Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Ovarian Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "poly ICLC", "type": "DRUG" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2007-10", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2014-01-14", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 1, "location_summary": "Newark, New Jersey", "locations": [ { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00553683" }, { "nct_id": "NCT00003594", "title": "Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "irinotecan", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1691, "start_date": "1998-10", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2020-04-29", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 430, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003594" }, { "nct_id": "NCT04853017", "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Minimal Residual Disease", "KRAS G12D", "KRAS G12R", "NRAS G12D", "NRAS G12R", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Cholangiocarcinoma", "Bile Duct Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "ELI-002 2P", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elicio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-10-15T11:13:26.936Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04853017" } ] }